Clinical trials: Focal Glomerulosclerosis
Focal Segmental Glomerulosclerosis, Minimal Change Disease
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Background: Podocyte diseases are a group of kidney conditions that include focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN).
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
- Trial name
- NCT06664814
- Testing
- ManNAc
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Focal Glomerulosclerosis
Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis
The purpose of this study is to assess the efficacy of Tacrolimus Treatment of patients with idiopathic focal segmental glomerulosclerosis.
- Trial name
- NCT00302536
- Testing
- Tacrolimus
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Nanjing University School of Medicine
Focal Segmental Glomerulosclerosis
Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)
Idiopathic Focal Segmental Glumero Sclerosis (FSGS) is not very common but important manifestation of kidney disease. FSGS has poor prognosis among the patterns of Idiopathic Nephrotic Syndrome (INS).
- Trial name
- NCT02382874
- Testing
- Intravenous injection
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Royan Institute
Focal Segmental Glomerulosclerosis, Chronic Kidney Diseases
Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis
The purpose of this study is to analyze the safety, renal function, metabolic disorders and quality of life data in patients with focal segmental glomerulosclerosis treated with endovascular infusion of bone marrow derived…
- Trial name
- STEFOG (NCT02693366)
- Testing
- Bone marrow stem cell
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Nephrotic Syndrome in Children, Minimal Change Disease
taVNS for FRNS in Children
Children with frequently relapsing nephrotic syndrome (FRNS) are exposed to prolonged courses of steroids and other immunosuppressant medications.
- Conditions
- Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- kidNEY-VNS (NCT05588063)
- Testing
- Transcutaneous auricular vagus nerve stimulation
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Nephrotic Syndrome, Membranous Nephropathy
Circulating Factors in Nephrotic Syndrome
A prospective observational study to investigate the treatment-associated changes of circulating factors associated with glomerular diseases among patients with de novo nephrotic syndrome admitted to hospital for a kidney biopsy.
- Conditions
- Nephrotic Syndrome, Membranous Nephropathy, Minimal Change Disease, Primary Focal Segmental Glomerulosclerosis
- Trial name
- NCT06315504
- Testing
- Observation
- Volunteers
- 104 people
- Sponsor
- Iain Bressendorff
Primary Focal Segmental Glomerulosclerosis
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
The purpose of this study is to determine whether Rituximab therapy is safe and effective in treating patients with the kidney condition, focal segmental glomerulosclerosis (FSGS), that is no longer responsive to traditional…
- Trial name
- NCT01573533
- Testing
- Rituximab
- Where
- 4 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Kidney Disease, Glomerular Disease
Kidney Disease Biomarkers
Kidney Disease Biomarkers Summary: This study will identify biomarkers (proteins and other molecules in the blood or urine) that may help scientists predict what kidney disease a patient has and whether a given patient would…
- Conditions
- Kidney Disease, Glomerular Disease, Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis
- Trial name
- NCT00255398
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Glomerulonephritis, Membranous, Glomerulosclerosis, Focal
Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental
This is a prospective randomized open-label pilot study to investigate the effect of mycophenolate mofetil treatment in patients with abnormal urine protein excretion due to membranous nephropathy (MN) or focal segmental…
- Trial name
- NCT00404833
- Testing
- prednisolone and mycophenolate mofetil, prednisolone and chlorambucil
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Hospital Authority, Hong Kong
Kidney Diseases, Diabetic Nephropathies
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
This is a phase 2a study evaluating the safety and tolerability of multiple ascending doses of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change…
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid
- Trial name
- NCT04387448
- Testing
- GFB-887
- Where
- 74 sites in United States
- Volunteers
- 96 people
- Sponsor
- Goldfinch Bio, Inc.
Focal Segmental Glomerulosclerosis
Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis
The aim of this clinical trial is to determine the effect and security of low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis.
- Trial name
- NCT00956059
- Testing
- prednisone, FK506, MMF, prednisone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xi'an Jiaotong University
Focal Segmental Glomerulosclerosis
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome
- Trial name
- NCT03703908
- Testing
- CCX140-B
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Amgen
Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
The purpose of this study was to assess the efficacy of the bleselumab regimen (basiliximab induction, tacrolimus, steroids and bleselumab) compared with the Standard of Care (SOC) regimen (basiliximab induction, tacrolimus…
- Trial name
- NCT02921789
- Testing
- Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF)
- Where
- 23 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Focal Segmental Glomerulosclerosis
Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor
This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with…
- Trial name
- NCT00816478
- Testing
- Galactose
- Volunteers
- 15 people
- Sponsor
- Northwell Health
Primary Membranous Nephropathy, Minimal Change Disease
A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease
This study will assess whether sibeprenlimab can help improve kidney disease in adults with primary membranous nephropathy (pMN) by reducing harmful antibodies linked to the disease.
- Conditions
- Primary Membranous Nephropathy, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- NCT07861113
- Testing
- Sibeprenlimab
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Focal Segmental Glomerulosclerosis
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
This is a pilot/feasibility, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to or at the time of kidney transplantation can prevent recurrent FSGS in children…
- Trial name
- NCT03763643
- Testing
- Rituximab, Plasmapheresis
- Where
- 12 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Minnesota
Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
The aim of this observational study is to assess humanistic burden among adults and children/adolescents with FSGS and IgAN as well as the burden and impact for patient care-partners in six countries (United States [US], United…
- Trial name
- HONUS (NCT05200871)
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 487 people
- Sponsor
- Travere Therapeutics, Inc.
Kidney Disease, Chronic
A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in…
- Trial name
- NCT05213624
- Testing
- BI 764198
- Where
- 54 sites in United States, Australia and 8 more
- Volunteers
- 67 people
- Sponsor
- Boehringer Ingelheim
Collapsing Glomerulopathy, Glomerulosclerosis, Focal Segmental
Podocyte Retinoids
This is a pilot study of retinoids for patients with unsatisfactory response to conventional treatment of nephrotic syndrome due to focal segmental glomerulosclerosis or minimal change disease, two renal disorders associated with…
- Trial name
- NCT00098020
- Testing
- Isotretinoin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Focal Segmental Glomerulosclerosis
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
This study will investigate whether GC1008, an antibody which neutralizes TGF-beta, is safe in treating patients with the disease called focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT00464321
- Testing
- GC1008
- Where
- 9 sites in United States, Germany and 2 more
- Volunteers
- 16 people
- Sponsor
- Genzyme, a Sanofi Company